ATC codes:
H02AB02
EMLc
Indication
Burkitt lymphoma including Burkitt leukaemia
ICD11 code:
2A85.6
INN
Dexamethasone
Medicine type
Chemical agent
List type
Complementary
(EML)
(EMLc)
(EMLc)
Formulations
Oral > Liquid:
2 mg per 5 mL (as sodium phosphate)
(EMLc)
Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
Oral > Solid > tablet: 2 mg (as dexamethasone base) (EMLc) ; 4 mg (as dexamethasone base)
Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
Oral > Solid > tablet: 2 mg (as dexamethasone base) (EMLc) ; 4 mg (as dexamethasone base)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Read more
about patents.
Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:
- to modify the listings to reflect the amount of dexamethasone in terms of dexamethasone salt or dexamethasone base.